Listen to Story As Finance Minister Nirmala Sitharaman announced during Budget 2025 that a new income tax bill would be introduced next week, anticipation became the central theme of the memes that ...

Sanofi’s fiscal year 2024 results were in line with expectations, with a noteworthy performance in their Vaccines division, particularly driven by Beyfortus. This offset a slight ...

Innovation was a key driver of our growth as launches already contributed 11% of sales, with Beyfortus becoming a blockbuster in its first full year of sales. “As we enter 2025, we expect continued, ...

Lantus sales rose 63.4% to €439.0 million. SNY & AZN’s Beyfortus Drives Vaccine Sales Total vaccine sales increased 10.8% to €2.2 billion, driven by Beyfortus sales in Europe. Sales of flu ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...

The company's research-and-development spending increased 24% on-year in the last quarter in an attempt to bring further blockbusters such as its respiratory syncytial virus vaccine Beyfortus to ...

Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with Beyfortus becoming a blockbuster in its first full year of sales. We exceeded our business EPS ...

Pharma launches up 56.5%, reaching sales of €0.8 billion, 8% of total sales, led by ALTUVIIIO Dupixent sales up 16.0% to €3.5 billion Vaccines sales up 10.8% to €2.2 billion, driven by Beyfortus sales ...

Sales of Beyfortus, a new treatment to protect newborns from a common respiratory virus, doubled to 841 million euros in the fourth quarter, beating estimates of 648 million euros. Sales of its ...

driven by Beyfortus sales in Europe Business EPS of €1.31, -11.0% at CER and -14.9% reported; IFRS EPS of €0.54 In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER 5 ...

1 Changes in net sales are at constant exchange rates (CER) unless stated otherwise (definition in Appendix 9). 2 To facilitate an understanding of operational performance, Sanofi comments on the ...